Septerna (SEPN) Expected to Announce Earnings on Thursday

Septerna (NASDAQ:SEPN) is projected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $15.5570 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. The company had revenue of $24.12 million for the quarter, compared to the consensus estimate of $20.44 million. On average, analysts expect Septerna to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Septerna Stock Down 4.2%

Shares of SEPN stock opened at $24.11 on Thursday. The firm has a market cap of $1.08 billion, a P/E ratio of -21.72 and a beta of 3.46. The company has a 50 day moving average of $26.69 and a 200-day moving average of $23.72. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63.

Insider Buying and Selling at Septerna

In related news, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the sale, the insider owned 793 shares in the company, valued at approximately $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $5,046,834.73. This represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Group One Trading LLC increased its position in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares during the last quarter. Global Retirement Partners LLC bought a new stake in Septerna during the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new position in Septerna in the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna in the 4th quarter worth $53,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Septerna in the 4th quarter worth $100,000.

Wall Street Analysts Forecast Growth

SEPN has been the subject of several research reports. Raymond James Financial assumed coverage on Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective for the company. Truist Financial upped their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research note on Tuesday, March 10th. Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, HC Wainwright boosted their price objective on Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $44.00.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.